Jeremy D Shapiro
Overview
Explore the profile of Jeremy D Shapiro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
2090
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tie J, Wang Y, Lo S, Lahouel K, Cohen J, Wong R, et al.
Nat Med
. 2025 Mar;
PMID: 40055522
Early data from the DYNAMIC study of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy (ACT) versus standard approach met its primary outcome demonstrating reduced ACT use without compromising 2-year recurrence-free survival...
2.
Kim G, Jalali A, Gard G, Yeung J, Chau H, Gately L, et al.
Clin Colorectal Cancer
. 2024 Nov;
24(1):72-81.
PMID: 39523153
Background: Surgery improves long-term survival for resectable, liver-only metastatic colorectal cancer (mCRC). With no consensus definition of "resectable" disease, decisions regarding resectability are reliant on the expertise and judgement of...
3.
Gupta A, OCallaghan C, Zhu L, Jonker D, Wong R, Colwell B, et al.
J Natl Cancer Inst
. 2024 Apr;
116(8):1313-1318.
PMID: 38656931
Introduction: Although contact days-days with health-care contact outside home-are increasingly adopted as a measure of time toxicity and treatment burden, they could also serve as a surrogate of treatment-related harm....
4.
Jiang D, Parshad S, Zhan L, Sim H, Siu L, Liu G, et al.
Clin Colorectal Cancer
. 2023 Sep;
22(4):457-463.
PMID: 37704538
Background: Cetuximab is a standard of care therapy for patients with RAS wild-type (WT) advanced colorectal cancer. Limited data suggest a wide variation in cetuximab plasma concentrations after standard dosing...
5.
Rattner J, Kopciuk K, Vogel H, Tang P, Shapiro J, Tu D, et al.
Cancer Med
. 2023 Jun;
12(15):16019-16031.
PMID: 37329221
Background: Trials of tyrosine kinase inhibitors (TKI) have not demonstrated dramatic benefits in advanced colorectal cancer (CRC), and this may be a function of poor patient selection. TKI-induced hypertension is...
6.
Gupta A, OCallaghan C, Zhu L, Jonker D, Wong R, Colwell B, et al.
JCO Oncol Pract
. 2023 Mar;
19(6):e859-e866.
PMID: 36881786
Purpose: The time spent in pursuing treatments for advanced cancer can be substantial. We have previously proposed a pragmatic and patient-centered metric of these time costs-which we term time toxicity-as...
7.
Rattner J, Kopciuk K, Vogel H, Tang P, Shapiro J, Tu D, et al.
Oncotarget
. 2022 Jan;
13:61-72.
PMID: 35028011
Purpose: Chemotherapy options for treating CRC have rapidly expanded in recent years, and few have predictive biomarkers. Oncologists are challenged with evidence-based selection of treatments, and response is evaluated retrospectively...
8.
Fontana E, Nyamundanda G, Cunningham D, Tu D, Cheang M, Jonker D, et al.
JCO Precis Oncol
. 2020 Oct;
4.
PMID: 33015526
Purpose: Metastatic colorectal cancers (mCRCs) assigned to the transit-amplifying (TA) CRCAssigner subtype are more sensitive to anti-epidermal growth factor receptor (EGFR) therapy. We evaluated the association between the intratumoral presence...
9.
Personalized Medicine-Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer
Koulis C, Yap R, Engel R, Jarde T, Wilkins S, Solon G, et al.
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32231042
Colorectal cancer (CRC) is the third most common cancer diagnosed worldwide and is heterogeneous both morphologically and molecularly. In an era of personalized medicine, the greatest challenge is to predict...
10.
Lau D, Burge M, Roy A, Chau I, Haller D, Shapiro J, et al.
Expert Rev Anticancer Ther
. 2020 Mar;
20(4):251-270.
PMID: 32186929
: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therapy enabled by better understanding of clinical behavior according to molecular subtype.: A review of the literature...